Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Systemic anti-cancer performance matrix

Prof Richard Sullivan, Kari Leung and Megan McLeod

Systemic anti-cancer performance matrix ( Prof Richard Sullivan, Kari Leung and Megan McLeod )

ESMO 2022: Best approaches to bladder preservation

Prof Morgan Rouprêt and Prof Nick James

ESMO 2022: Best approaches to bladder preservation ( Prof Morgan Rouprêt and Prof Nick James )

Tislelizumab demonstrates non-inferior OS compared to sorafenib for treating hep...

Prof Masatoshi Kudo - Kindai University Faculty of Medicine, Osaka, Japan

Tislelizumab demonstrates non-inferior OS compared to sorafenib for treating hepatocellular carcinoma ( Prof Masatoshi Kudo - Kindai University Faculty of Medicine, Osaka, Japan )

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced br...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Cancer survivors' stories: An African perspective

Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation

Cancer survivors' stories: An African perspective ( Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation )

ESMO 2022: Breast and ovarian trial analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

ERMES study suggests a strategy of de-escalation with only cetuximab in first li...

Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy

ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC ( Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy )

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible loca...

Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York Cit...

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-li...

Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )

ESMO 2022: Highlights, commentary and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Ideal duration of androgen deprivation therapy with post-operative radiotherapy ...

Prof Chris Parker - Institute of Cancer Research, Sutton, UK

Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )

More from ecancer